NEW YORK – Apollomics has launched the Phase II portion of the Phase I/II SPARTA trial for its investigational c-MET inhibitor APL-101, which will enroll patients with different tumors and MET alterations.
NEW YORK – Apollomics has launched the Phase II portion of the Phase I/II SPARTA trial for its investigational c-MET inhibitor APL-101, which will enroll patients with different tumors and MET alterations.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.